Pasithea Therapeutics Corp. (KTTA): Total Liabilities
$5.02M
As of 2025-12-31
$1.87M
As of 2026-06-30
+23.2%
3-year compound annual growth
n/m
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $5.02M | +291.6% | 2026-03-30, Balance as of period end |
| 2024-12-31 | $1.28M | -52.8% | 2026-03-30, Balance as of period end |
| 2023-12-31 | $2.72M | +1.4% | 2025-03-24, Balance as of period end |
| 2022-12-31 | $2.68M | +41.1% | 2024-03-29, Balance as of period end |
| 2021-12-31 | $1.90M | n/m | 2023-03-30, Balance as of period end |
| 2020-12-31 | $6.6K | n/a | 2022-03-30, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Pasithea Therapeutics Corp. (KTTA) | 2025-12-31 | $5.02M | +291.6% |
| ProPhase Labs, Inc. (PRPH) | 2025-12-31 | $56.36M | +0.9% |
| Palvella Therapeutics, Inc. (PVLA) | 2025-12-31 | $31.58M | +23.2% |
| ALX Oncology Holdings Inc (ALXO) | 2025-12-31 | $33.06M | -3.2% |
| Scynexis Inc (SCYX) | 2025-12-31 | $9.65M | -72.9% |
| Q32 Bio Inc. (QTTB) | 2025-12-31 | $19.76M | -77.2% |
| Rani Therapeutics Holdings, Inc. (RANI) | 2025-12-31 | $17.11M | -48.4% |
| AN2 Therapeutics, Inc. (ANTX) | 2025-12-31 | $8.89M | -13.2% |
| Biomea Fusion, Inc. (BMEA) | 2025-12-31 | $29.02M | +2.3% |
Compare KTTA, PRPH, PVLA, ALXO side by side · Screen every company in Pharmaceutical Preparations ↗